ESTUDIO DE FASE 2/3, MULTICÉNTRICO, ALEATORIZADO, ABIERTO, DE 3 GRUPOS Y DOS ETAPAS, DE ASP2215 (GILTERITINIB), LA COMBINACIÓN DE ASP2215 MÁS AZACITIDINA Y AZACITIDINA SOLA EN EL TRATAMIENTO DE PACIENTES CON LEUCEMIA MIELOIDE AGUDA DE DIAGNÓSTICO RECIENTE CON MUTACIÓN DE FLT3 NO ELEGIBLES PARA QUIMIOTERAPIA DE INDUCCIÓN INTENSIVA.

Article. 10.1016/j.thromres.2018.12.027. 2019

BEAM Vs Cyclophosphamide-Based Conditioning Regimen in Aggressive Multiple Sclerosis: A Retrospective Analysis of European Blood and Marrow Transplantation Society

Saccardi, Riccardo; (...); Snowden, John A.

Meeting Abstract. 10.1182/blood-2019-125233. 2019

Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.

Fernandez Rivera C; (...); Hernandez D

Article. 10.1111/ctr.14550. 2022

BK Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplantation in the Pediatric Population

Perez-Huertas, P; (...); Poveda-Andres, JL

Article. 10.1177/1043454216631952. 2017

Breakthrough invasive fungal disease in high-risk hematologic malignancies in children: a single-center experience

Garcia-Robles, AA; (...); Fernandez-Navarro, JM

Meeting Abstract. 2017

Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience

Gayoso, J; (...); Diez-Martin, JL

Article. 10.1038/bmt.2016.115. 2016

Central Nervous System Involvement in Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation.

Balaguer-Rosello, Aitana; (...); Sanz, Jaime

Article. 10.1016/j.jtct.2020.12.019. 2021

CLINICAL APPLICATION OF THE MASSIVE SEQUENCING ADDRESSED IN ACUTE MYELOBLASTIC LEUKEMIA

Garcia, ML; (...); Gonzalez, EB

Meeting Abstract. 2017

Clinical Benefit of Glasdegib Plus Low-Dose Cytarabine in Patients with De Novo and Secondary Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial

Heuser, M; (...); Cortes, JE

Meeting Abstract. 10.1016/j.clml.2019.07.116. 2019

Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial (vol 100, pg 1181, 2021)

Heuser, Michael; (...); Cortes, Jorge E.

Article. 10.1007/s00277-021-04545-5. 2021

Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.

Heuser M; (...); Cortes JE

Article. 10.1007/s00277-021-04465-4. 2021

Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients

Article. 10.1016/j.thromres.2021.07.009. 2021

Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid

Sanchez, R; (...); Martinez-Lopez, J

Article. 10.1007/s00277-017-3002-1. 2017

Clinical Effectiveness of Influenza Vaccination After Allogeneic Hematopoietic Stem Cell Transplantation: A Cross-sectional, Prospective, Observational Study

Pinana, JL; (...); Navarro, D

Article. 10.1093/cid/ciy792. 2019

Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib

Perl, AE; (...); Tiu, RV

Meeting Abstract. 2021

Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.

Perl, Alexander E.; (...); Altman, Jessica K.

Article. 10.1038/s41408-022-00677-7. 2022

Clinical Outcomes of Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Hematopoietic Stem Cell Transplantation Who Fail Rituximab: A Multinational, Retrospective Chart Review Study

Sanz, Jaime; (...); Mohty, Mohamad

Meeting Abstract. 10.1182/blood-2021-147296. 2021

Clinical pharmacy services: from cost-effectiveness analysis to a productivity indicators model

Nogueras, A; (...); Calleja, MA

Letter. 10.1136/ejhpharm-2019-001905. 2019

Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Bazarbachi, A; (...); Mohty, M

Article. 10.3324/haematol.2019.243410. 2020

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Daver, Naval G.; (...); Kantarjian, Hagop M.

Meeting Abstract. 10.1182/blood-2019-128648. 2019

Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy

Labrador, J; (...); GATLA Grp

Article. 10.1080/10428194.2018.1522438. 2019

Clinical significance of Pneumocystis jirovecii DNA detection by real-time PCR in hematological patient respiratory specimens.

Piñana JL; (...); Navarro D

Letter. 10.1016/j.jinf.2020.01.001. 2020

Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics

Alonso, CM; (...); Barragan, E

Article. 10.1016/j.jmoldx.2018.09.009. 2019

Clinician Concepts of Cure in Adult Relapsed and Refractory Philadelphia-Negative B Cell Precursor Acute Lymphoblastic Leukemia: A Delphi Study

Bassan, R; (...); Cong, Z

Article. 10.1007/s12325-019-00910-z. 2019

Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes

Martinez-Losada, C; (...); Sanchez-Garcia, J

Letter. 10.3324/haematol.2018.188433. 2018

Clonal Hematopoiesis Landscape in Patients with De Novo Acute Myeloid Leukemia By Deep Sequencing

Ibanez, Mariam; (...); Cervera, Jose

Meeting Abstract. 10.1182/blood.V128.22.598.598. 2016

Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitor-Enriched Cord Blood, to Double Cord Blood Unit Transplantation

Stiff, PJ; (...); Sanz, G

Article. 10.1016/j.bbmt.2018.02.012. 2018

Collaborative model of home delivery program in haemophilia through an association of patients

Megias-Vericat, JE; (...); Bonanad, S

Meeting Abstract. 2018

Common seasonal respiratory virus infections in allogeneic stem cell transplant recipients during the SARS-COV-2 pandemic.

De La Puerta R; (...); Piñana JL

Article. 10.1038/s41409-021-01319-5. 2021

Community acquired respiratory virus infections in adult patients undergoing umbilical cord blood transplantation.

Montoro J; (...); Piñana JL

Article. 10.1038/s41409-020-0943-0. 2020

Comparative Study of Treosulfan Plus Fludarabine (FT14) with Busulfan Plus Fludarabine (FB4) for Acute Myeloid Leukemia in First or Second Complete Remission: An Analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)

Gavriilaki, Eleni; (...); Mohty, Mohamad

Meeting Abstract. 10.1182/blood-2021-146303. 2021

Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT

Kharfan-Dabaja, MA; (...); Mohty, M

Article. 10.1038/s41409-021-01317-7. 2021

COMPARISON OF AZACITIDINE AND DECITABINE FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: SYSTEMATIC REVIEW AND META-ANALYSIS

Saiz-Rodriguez, M.; (...); Labrador, J.

Meeting Abstract. 2020

Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Post-transplant Cyclophosphamide in Patients with Acute Leukemia.

Nagler A; (...); Mohty M

Article. 10.1158/1078-0432.CCR-20-2809. 2020

Comparison of Haploidentical Peripheral Blood Cell Transplantation Using Post-Transplant Cyclophosphamide With Double Cord Blood Transplantation in Adults With Acute Leukemia

Ruggeri, A; (...); Mohty, M

Meeting Abstract. 2021

Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia

Ribera, JM; (...); PETHEMA Grp

Article. 10.1016/j.leukres.2018.03.010. 2018

Comparison of Matched Sibling, Unrelated and Haploidentical Donor Transplants Using Post-Transplant Cyclophosphamide in Patients with Acute Myeloid Leukemia, a Study of the ALWP EBMT

Sanz, Jaime; (...); Mohty, Mohamad

Meeting Abstract. 2020

Comparison of pharmacokinetic estimates using generic and specific population pharmacokinetic models of plasma-derived factor VIII/VWF using WAPPS-Hemo

Meeting Abstract. 2020

Comparison of transfusion requirements in adult patients undergoing Haploidentical or single-unit umbilical cord blood stem cell transplantation

Solves, P; (...); Sanz, GF

Article. 10.1111/ejh.13270. 2019

Complex Karyotype with >= 3 Cytogenetic Alterations is a New Marker of Worse Prognosis in Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Genesca, Eulalia; (...); Maria Ribera, Josep

Meeting Abstract. 2020

Copper deficiency: a cause of misdiagnosis of myelodysplastic syndrome

Villalba, A; (...); Senent, L

Letter. 10.1007/s00277-018-3334-5. 2018

Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukaemia in first remission

Baron, F; (...); Nagler, A

Article. 10.1111/joim.12870. 2019

Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.

Martínez-Cuadrón D; (...); CETLAM and PETHEMA groups

Article. 10.1007/s00277-018-3277-x. 2018

Correction to: Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus.

Montesinos P; (...); Sanz MÁ

Correction. 10.1007/s00277-020-03933-7. 2020

Correction: Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients.

Spyridonidis A; (...); Mohty M

Correction. 10.1038/s41409-020-0835-3. 2020

Corrigendum to "Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study" [Leuk. Res. 92 (March) (2020) 106352].

Rodríguez-Medina C; (...); Montesinos P

Correction. 10.1016/j.leukres.2020.106388. 2020

COST MINIMIZATION ANALYSIS OF RITUXIMAB BIOSIMILAR VERSUS REFERENCE RITUXIMAB IN THE TREATMENT OF FOLLICULAR LYMPHOMA

Gironella, M.; (...); Oyaguez, I

Meeting Abstract. 2019

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain

Mareque, M; (...); Sierra, J

Article. 10.2147/CEOR.S302097. 2021

Cost-effectiveness analysis of implementing an antimicrobial stewardship program in critical care units

Ruiz-Ramos, J; (...); Ramirez, P

Article. 10.1080/13696998.2017.1311903. 2017

Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.

Poveda JL; (...); Torres C

Article. 10.1080/14737167.2019.1635014. 2020

COST-EFFECTIVENESS OF CLADRIBINE TABLETS AND FINGOLIMOD IN THE TREATMENT OF REMITTING MULTIPLE SCLEROSIS WITH HIGH DISEASE ACTIVITY IN SPAIN

Trillo, JL; (...); Torres, C

Meeting Abstract. 10.1016/j.jval.2018.09.2029. 2018

COST-EFFECTIVENESS OF GEMTUZUMAB OZOGAMICIN IN COMBINATION WITH STANDARD CHEMOTHERAPY IN FIRST-LINE TREATMENT IN PATIENTS WITH CD-33-POSITIVE ACUTE MYELOID LEUKEMIA IN SPAIN

Montesinos, P.; (...); Guinea, J. M.

Meeting Abstract. 2020

Cost-Effectiveness Of Midostaurin In The Treatment Of Acute Myeloid Leukemia With The FLT3 Mutation In Spain

Arenaza, A; (...); Vinent, JL

Article. 10.2147/CEOR.S222879. 2019

Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain

Camara, R; (...); Grau, S

Article. 10.1007/s12325-017-0600-1. 2017

Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Grau, S; (...); Gozalbo, I

Article. 10.1007/s10198-017-0907-5. 2018

COSTS OF THE MANAGEMENT OF HEMOPHILIA A WITH INHIBITORS IN SPAIN

Bonanad, S; (...); Gonzalez-Dominguez, A

Meeting Abstract. 2020

Costs of the management of hemophilia A with inhibitors in Spain

Bonanad, S; (...); Gonzalez-Dominguez, A

Article. 10.33393/grhta.2021.2234. 2021

Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate (R)) and BAY 81-8973 (KovaltryA (R)) in patients with severe or moderate haemophilia A in prophylaxis

Letter. 10.1111/hae.13733. 2019

Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products

Eduardo Megias, Juan; (...); Iorio, Alfonso

Meeting Abstract. 10.1182/blood-2019-127946. 2019

CURRENT STATE OF ACUTE MYELOID LEUKEMIA IN SPAIN: RESULTS FROM A DELPHI STUDY ON EPIDEMIOLOGY, DISEASE MANAGEMENT AND UNMET NEEDS

Montesinos, P; (...); Sierra, J

Meeting Abstract. 2018

Current status of acute myeloid leukaemia in Spain: Results from a Delphi study on its epidemiology, disease management and unmet clinical needs.

Montesinos P, Gil A, Sierra J

Letter. 10.1016/j.medcli.2020.04.032. 2020

Current Status of CPX-351 Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome.

Alotaibi, Shaykhah; (...); Aljurf, Mahmoud

Article. 10.1016/j.clml.2022.02.008. 2022

Cytomegalovirus DNA load monitoring in stool specimens for anticipating the occurrence of intestinal acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: Is it of any value?

Bueno F; (...); Navarro D

Article. 10.1111/tid.13440. 2020

Challenges in Clinical Metaproteomics Highlighted by the Analysis of Acute Leukemia Patients with Gut Colonization by Multidrug-Resistant Enterobacteriaceae

Rechenberger, J; (...); Kuster, B

Article. 10.3390/proteomes7010002. 2019

Challenges in the diagnosis and treatment of secondary acute myeloid leukemia

Ossenkoppele, G, Montesinos, P

Review. 10.1016/j.critrevonc.2019.03.003. 2019

Changes in health-related quality of life in patients with newly diagnosed acute myeloid leukemia receiving ivosidenib plus azacitidine or placebo plus azacitidine.

Schuh, Andre C.; (...); Montesinos, Pau

Meeting Abstract. 2022

Changes in nutritional status, body composition and associated symptomatology in hospitalized patients undergoing bone marrow transplantation: prospective longitudinal study

Cabanas-Alite, L; (...); Pinana, LL

Article. 10.14306/renhyd.25.2.1098. 2021

Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants.

Cicconi, L; (...); Abla, O

Article. 10.1038/s41408-021-00561-w. 2021

Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols.

Sobas M; (...); PETHEMA, HOVON, PALG, GATLA cooperative groups

Article. 10.1111/ejh.13346. 2020

Characteristics and Outcome of Early T Cell Precursor ALL (ETP-ALL) Patients Treated with High-Risk Spanish Pethema Protocols

Genesca, E; (...); Ribera, JM

Meeting Abstract. 10.1182/blood-2018-99-114559. 2018

Characteristics and Outcome of Older Patients with Acute Promyelocytic Leukemia Front-Line Treated with or without Arsenic Trioxide - an International Collaborative Study

Kayser, S; (...); Montesinos, P

Meeting Abstract. 10.1182/blood-2018-99-111768. 2018

Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4

Kayser, Sabine; (...); Schlenk, Richard F.

Meeting Abstract. 10.1182/blood-2021-150281. 2021

Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4.

Kayser, Sabine; (...); Schlenk, Richard F.

Meeting Abstract. 10.3324/haematol.2022.281137. 2022

Characteristics and outcome of patients with core binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study.

Kayser S; (...); Levis MJ

Article. 10.3324/haematol.2021.278645. 2022

Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia.

Martinez-Cuadron, David; (...); On Behalf Of The Pethema Group

Article. 10.3390/cancers14112817. 2022

Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group

Palanques-Pastor, Tomas; (...); Montesinos, Pau

Article. 10.1080/10428194.2021.1948031. 2021

Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort

Stahl, M; (...); Zeidan, AM

Meeting Abstract. 10.1182/blood-2018-99-112974. 2018

CHARACTERIZATION OF THE GENOMIC AND TRANSCRIPTOMIC PROFILE OF THE ACUTE MYELOID LEUKEMIA (AML) SUBGROUP "CHROMATIN-SPLICEOSOME"

Alessandro, Liquori; (...); Zamora Jose, Cervera

Meeting Abstract. 2020

Characterization of three new HLA Class I Alleles in Spanish Caucasians, HLA-A02:620, HLA-B27:150 and HLA-B*07:05:01:02

Balas, A; (...); Vicario, JL

Article. 10.1111/iji.12317. 2017

Chemotherapy or Allogeneic Transplantation in High-Risk Philadelphia Chromosome-Negative Adult Lymphoblastic Leukemia.

Ribera JM; (...); Orfao A

Article. 10.1182/blood.2020007311. 2020

Chromosomal Abnormalities and Prognosis in NPM1 -Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts.

Angenendt, L; (...); Schliemann, C

Article. 10.1200/JCO.19.00416. 2019

Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT.

Vincent, Laure; (...); Beksac, Meral

Letter. 10.1038/s41409-021-01560-y. 2022

Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review

Review. 10.1080/17512433.2019.1573668. 2019

Decitabine as Salvage Therapy after Azacitidine in AML

De La Fuente, A; (...); Montesinos, P

Meeting Abstract. 2019

Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project

Blade, J; (...); Lizan, L

Article. 10.1136/bmjopen-2017-018850. 2018

Design and rationale for a real-world prospective, multicenter registry of myocardial revascularization failure and secondary revascularization: The REVASEC study.

Salinas P; (...); Escaned J

Article. 10.1016/j.carrev.2021.11.015. 2021

Detection of plasmid-mediated colistin resistance, mcr-1 gene, in Escherichia coli isolated from high-risk patients with acute leukemia in Spain

Lalaoui, R; (...); Rolain, JM

Article. 10.1016/j.jiac.2019.03.007. 2019

Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation.

Hernández-Boluda JC; (...); Yakoub-Agha I

Article. 10.1038/s41375-020-0815-z. 2020

Determinants of Survival in Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Cell Transplantation: A Study by the Chronic Malignancies Working Party of EBMT

Hernandez-Boluda, JC; (...); Yakoub-Agha, I

Meeting Abstract. 2020

Determining the value contribution of emicizumab (Hemlibra (R)) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis

Alvarez-Roman, MT; (...); Badia, X

Article. 10.1177/2284240319880534. 2019

DETERMINING THE VALUE OF EMICIZUMAB FOR THE PROPHYLAXIS OF SEVERE HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)

Alvarez, E.; (...); Badia, F. J.

Meeting Abstract. 2019

Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry.

Shouval R; (...); Nagler A

Article. 10.1016/S2352-3026(20)30394-X. 2021

DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN

Poveda, J. L.; (...); Vitoria, I

Meeting Abstract. 2019

Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain

Badia, X; (...); Poved, JL

Article. 10.1080/21678707.2019.1652163. 2019

Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia

Megias-Vericat, JE; (...); Spanish PETHEMA Grp

Article. 10.4084/MJHID.2019.016. 2019

Differentiation Syndrome with Lower-intensity Treatments for Acute Myeloid Leukemia.

Fathi, Amir T; (...); de Botton, Stephane

Review. 10.1002/ajh.26142. 2021

Diffusion tensor imaging as a prognostic biomarker for motor recovery and rehabilitation after stroke

Puig, J; (...); Pedraza, S

Review. 10.1007/s00234-017-1816-0. 2017

Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia

Review. 10.1007/s00277-020-04186-0. 2020

Early experience with compassionate use of 2 hydroxypropyl-beta-cyclodextrin for Niemann-Pick type C disease: review of initial published cases

Review. 10.1007/s10072-017-2833-9. 2017

Economic Burden of Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients: A Spanish Multicenter, Retrospective Study

Vazquez, L; (...); Solano, C

Meeting Abstract. 2020

Economic impact of optimising antiretroviral treatment in human immunodeficiency virus-infected adults with suppressed viral load in Spain, by implementing the grade A-1 evidence recommendations of the 2015 GESIDA/National AIDS Plan

Ribera, E; (...); Hernandez-Novoa, B

Article. 10.1016/j.eimc.2016.11.015. 2018

Efecto de la adición de fortificantes y de módulo de proteínas en la osmolalidad de la leche materna donada.

Torres Martínez E; (...); Vento M

Article. 10.1016/j.anpedi.2020.03.009. 2020

Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML).

Dinardo, CD; (...); Dohner, H

Meeting Abstract. 2020

Effect of gilteritinib on survival in patients with FLT3-mutated (FLT3(mut+)) relapsed/refractory (RR) AML who have common AML co-mutations or a high FLT3-ITD allelic ratio.

Levis, MJ; (...); Bahceci, E

Meeting Abstract. 2019

EFFECT OF MISSENSE MUTATIONS IN THE SPLICING OF PATIENTS WITH ACUTE MYELOID LEUKAEMIA

Morote-Faubel, M.; (...); Cervera, J.

Meeting Abstract. 2019

Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed/refractory (R/R) mIDH1 acute myeloid leukemia (AML): Results from a planned interim analysis of a phase 2 clinical trial.

De Botton, Stephane; (...); Fenaux, Pierre

Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.7006. 2021

EFFECTIVENESS AND TOXICITY OF THE USE OF INOTUZUMAB (INO) IN PATIENTS WITH RESISTANT OR RECALLING (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (LAL). STUDY OF PATIENTS INCLUDED IN INO'S EXPANDED USE PROGRAM

Ribera Santasusana, J. M.; (...); Valero, M.

Meeting Abstract. 2021

Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment

Palanques-Pastor T; (...); Poveda Andrés JL

Article. 10.1159/000517813. 2021

EFFICACY AND SAFETY OF BUDESONIDE AS FIRST LINE TREATMENT IN PATIENTS WITH AUTOIMMUNE HEPATITIS: SPANISH MULTICENTER STUDY

Diaz-Gonzalez, Alvaro; (...); Carlota Londono, Maria

Meeting Abstract. 2021

Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial.

Zeiser R; (...); Chen YB

Article. 10.1016/S2352-3026(21)00367-7. 2022

Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301) : a randomised, multicentre, double-blind, phase 3 trial

Zeiser, Robert; (...); Chen, Yi-Bin

Article. 10.1016/S2352-3026(21)00367-7. 2022

Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia

Ribera, JM; (...); PETHEMA Group, Spanish Society of Hematology

Article. 10.1080/10428194.2017.1397661. 2018

Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial

Cortes, JE; (...); Levis, MJ

Meeting Abstract. 10.1182/blood-2018-99-110439. 2018

Efficacy and Safety of Single-Agent Quizartinib (Q), Potent and SeleEfficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial

Cortes, JE; (...); Levis, MJ

Meeting Abstract. 2019

Efficacy and Safety of Single-Agent Quizartinib, a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) With FLT3-Internal Tandem Duplication (FLT3-ITD) - Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial

Jonas, BA; (...); Levis, MJ

Meeting Abstract. 10.1016/j.clml.2019.07.097. 2019

eLearning of pharmacokinetic monitoring in hemophilia with application in the clinical practice

Bonanad, S; (...); Megias-Vericat, JE

Meeting Abstract. 2018

Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.

Solana-Altabella, Antonio; (...); Montesinos, Pau

Article. 10.1080/14728214.2021.2009800. 2022

Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial.

Smith CC; (...); Bahceci E

Article. 10.1182/blood-2019-122620. 2019

Emerging strategies for the treatment of older patients with acute myeloid leukemia

Sanz MA; (...); Venditti A

Review. 10.1007/s00277-016-2666-2. 2016

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.

DiNardo CD; (...); Döhner H

Article. 10.1016/S1470-2045(21)00494-0. 2021

Enasidenib vs conventional care in mutant-IDH2 relapsed/refractory acute myeloidleukemia: a randomized, phase 3 trial.

de Botton, Stephane; (...); DiNardo, Courtney D.

Article. 10.1182/blood.2021014901. 2022

Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial.

Dohner, H; (...); Roboz, GJ

Meeting Abstract. 2020

EVALUATING REAL LIFE CRITERIA THAT COULD DRIVE PRICING & REIMBURSEMENT (P&R) APPROVAL OF ORPHAN DRUGS (ODS) IN SPAIN

Badia, F. J.; (...); Shepherd, J.

Meeting Abstract. 2019

Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoeitic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years.

Bazarbachi A; (...); Mohty M

Article. 10.1158/1078-0432.CCR-20-3134. 2020

Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients.

Boluda B; (...); Montesinos P

Article. 10.1080/10428194.2021.1938031. 2021

Evolving treatment patterns and outcomes in older patients (=60 years) with AML: changing everything to change nothing?

Martínez-Cuadrón D; (...); Montesinos P

Article. 10.1038/s41375-020-01058-4. 2020

Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-vs-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation.

Montoro, Juan; (...); Sanz, Jaime

Article. 10.1111/ejh.13529. 2021

Experience of Home Delivery Program in Haemophilia Through an Association of Patients

Megias Vericat, J. E.; (...); Bonanad Boix, S.

Meeting Abstract. 2017

Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Pemmaraju, Naveen; (...); Daver, Naval

Meeting Abstract. 10.1182/blood-2021-146666. 2021

EXPLOITING CUTTING-EDGE TECHNOLOGIES TO ANALYZE LOSS OF HLA IN A MULTICENTRIC COHORT OF POST-TRANSPLANTATION RELAPSES: RESULTS FROM THE HLALOSS GLOBAL COLLABORATIVE STUDY

Vago, L.; (...); Fleischhauer, K.

Meeting Abstract. 2018

Exploratory analysis for the implementation of antineoplastic logarithmic dose banding

Albert-Mari, A; (...); Poveda-Andres, JL

Article. 10.1007/s11096-018-0714-9. 2018

EXTENDED MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD EXTENSION STUDY

F, de Andres-Nogales; (...); Martinez, M.

Meeting Abstract. 2019

Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-vs-host disease: Pharmacoeconomic assessment of hospital resource use in Spain.

Boluda, Blanca; (...); Montesinos, Pau

Article. 10.1002/jca.21901. 2021

Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation

Solves P; (...); Carpio N

Article. 10.1007/s00277-017-3168-6. 2018

Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis

Fox, ML; (...); Valcarcel, D

Article. 10.1080/10428194.2020.1788015. 2020

Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease

Beltran, B; (...); Nos, P

Article. 10.1159/000492626. 2019

Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report

Fernandez-Sanchez, M; (...); Poveda-Andres, JL

Article. 10.1002/bdr2.1942. 2021

FINAL RESULTS OF THE LAL-RI 08 PROTOCOL FOR ADOLESCENTS AND YOUNG ADULTS (AAJ) WITH LYMPHOBLASTIC ACUTE LEUKEMIA (LAL) OF STANDARD RISK (RE)

Santasusana, JMR; (...); Vale, AODCE

Meeting Abstract. 2018

First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia.

Salamero, Olga; (...); Somervaille TCP

Article. 10.1200/JCO.19.03250. 2020

Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia

Pallarès V; (...); Casanova, I

Article. 10.3390/cancers10110436. 2018

Follow-up of patients with FLT3-mutated R/R AML in the phase 3 ADMIRAL trial.

Perl, Alexander E.; (...); Levis, Mark J.

Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.7013. 2021

Follow-up of Patients With FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukaemia in the Phase 3 ADMIRAL Trial

Perl, Alexander E.; (...); Levis, Mark J.

Meeting Abstract. 2022

Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.

Perl AE; (...); Levis MJ

Article. 10.1182/blood.2021011583. 2022

Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia

Genesca, E; (...); Ribera, JM

Article. 10.1186/s13045-018-0639-8. 2018

FREQUENCY AND CLINICAL IMPACT OF CDKN2A/B GENE LOCUS IN AN ADULT T-ALL COHORT OF PATIENTS ENROLLED IN THE SPANISH PETHEMA GROUP PROTOCOLS

Genesca, E; (...); Ribera, JM

Meeting Abstract. 2017

Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia

Motllo C; (...); PETHEMA Group, Spanish Society of Hematology

Article. 10.1080/10428194.2017.1326596. 2018

Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols

Motlló C; (...); PETHEMA Group, Spanish Society of Hematology

Article. 10.1080/10428194.2016.1177182. 2017

Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain.

Ribera, Josep-Maria; (...); Pinana, Jose-Luis

Article. 10.1016/j.clml.2021.06.024. 2021

Frequency, characteristics and outcomes of Lymphoproliferative Disorders After Allogeneic Stem Cell Transplant: results of a multicenter study from the Grupo Espanol de Trasplante Hematopoyetico (GETH)

Garcia Cadenas, Irene; (...); Solano, Carlos

Meeting Abstract. 2018

Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH)

Garcia-Cadenas, I; (...); Spanish Grp Blood & Marrow Tran

Article. 10.1111/ejh.13226. 2019

FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study

Cortes, JE; (...); Baer, MR

Meeting Abstract. 10.1182/blood-2018-99-114126. 2018

FUNCTIONAL CLASSIFICATION OF DEEP INTRONIC VARIANTS IN PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIA

Liquori, A.; (...); Cervera Zamora, J.

Meeting Abstract. 2019

FUNCTIONAL RECLASSIFICATION THROUGH MINIGENE TESTS OF MISSENSE VARIANTS WITH EFFECT ON SPLICING IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

Morote-Faubel, Mireya; (...); Cervera, Jose

Meeting Abstract. 2020

Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 Maintenance Therapy in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Trial

Ravandi, Farhad; (...); Dombret, Herve

Meeting Abstract. 2020

Gastrointestinal events and management strategies for patients with acute myeloid leukemia (AML) in first remission receiving oral azacitidine (Oral-AZA) in the randomized, placebo-controlled, phase 3 QUAZAR AML-001 maintenance trial

Pfeilstocker, M.; (...); Dombret, H.

Meeting Abstract. 2021

Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia.

Mosquera Orgueira A; (...); Bello López JL

Article. 10.1371/journal.pone.0247093. 2021

GENES BELONGING TO THE SWI/SNF CHROMATIN REMODELING COMPLEXES ARE MUTATED AT HIGH FREQUENCY IN RARE T(11;17)(Q23;Q21)/ZBTB16-RARA ACUTE MYELOID LEUKEMIA PATIENTS

Fabiani, E.; (...); Voso, M. T.

Meeting Abstract. 2020

Genomic characterization of Citrobacter freundii strains coproducing OXA-48 and VIM-1 carbapenemase enzymes isolated in leukemic patient in Spain

Lalaoui, R; (...); Rolain, JM

Article. 10.1186/s13756-019-0630-3. 2019

GETH-CLL4: Long-term follow-up of a pilot trial evaluating the addition of ofatumumab to the conditioning regimen of patients with chronic lymphocytic leukemia undergoing allogeneic HCT

Montesinos, Pau; (...); Delgado, Julio

Meeting Abstract. 2018

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML.

Perl AE; (...); Levis MJ

Article. 10.1056/NEJMoa1902688. 2019

Gilteritinib prolongs survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukaemia who have common AML comutations or a high FLT3-internal tandem duplication allelic ratio

Levis, MJ; (...); Bahceci, E

Meeting Abstract. 2020

Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial

Perl, AE; (...); Levis, MJ

Meeting Abstract. 10.1158/1538-7445.AM2019-CT184. 2019

GILTERITINIB SIGNIFICANTLY PROLONGS OVERALL SURVIVAL IN PATIENTS WITH FLT3-MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA: RESULTS FROM THE PHASE 3 ADMIRAL TRIAL

Perl, A. E.; (...); Levis, M. J.

Meeting Abstract. 2019

Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia: results from the phase 3 ADMIRAL trial

Perl, A. E.; (...); Levis, M. J.

Meeting Abstract. 2019

Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation.

Ballesta-López O; (...); Montesinos P

Review. 10.2217/fon-2020-0700. 2020

Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: BRIGHT AML 1003 final report and four-year overall survival (OS) follow-up.

Heuser, M; (...); Cortes, JE

Meeting Abstract. 2020

Glasdegib plus low-dose cytarabine in acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS): BRIGHT AML 1003 final report and 4-year overall survival follow-up

Heuser, M; (...); Cortes, JE

Meeting Abstract. 2020

Glasdegib Plus Low-Dose Cytarabine in Acute Myeloid Leukemia or Myelodysplastic Syndrome: BRIGHT AML 1003 Final Report and 4-Year Overall Survival Follow-Up

Heuser, Michael; (...); Cortes, Jorge E.

Meeting Abstract. 2020

Glasdegib with LDAC in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) Unsuitable for Intensive Chemotherapy: Effects on Transfusions and Marrow Recovery vs LDAC Alone

Wang, ES; (...); Cortes, JE

Meeting Abstract. 10.1016/j.clml.2019.07.114. 2019

Guide to Good Humanization Practices in Patients with Rare Diseases. who vadis

Poveda Andres, Jose Luis

Editorial Material. 2022

Haemodialysis significantly reduces serum levetiracetam levels inducing epileptic seizures: Case report

Company-Albir, MJ; (...); Poveda, JL

Article. 10.1111/jcpt.12568. 2017

Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML

Kwon M; (...); Diez-Martin JL

Article. 10.1038/bmt.2017.36. 2017

Haploidentical non-manipulated stem cell transplant in patients with non-hodgkin lymphoma: Spanish experience

Dorado, N; (...); Diez-Martin, JL

Meeting Abstract. 2019

Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Non-Hodgkin Lymphoma: The Spanish Experience

Dorado, N; (...); Kwon, M

Meeting Abstract. 2020

Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Cancers A Systematic Review and Meta-analysis

Gagelmann, N; (...); Kroger, N

Review. 10.1001/jamaoncol.2019.3541. 2019

Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Nagler, Arnon; (...); Mohty, Mohamad

Meeting Abstract. 10.1182/blood-2021-144558. 2021

Hazardous drugs levels in compounding area surfaces of Hospital Pharmacies Services: multicentric study

Valero-Garcia, S; (...); Spanish Hosp Pharmacy Units

Article. 10.7399/fh.10935. 2018

Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study

Solana-Altabella, Antonio; (...); Martinez-Cuadron, David

Article. 10.3390/cancers14081921. 2022

Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain.

Solana-Altabella A; (...); Montesinos P

Article. 10.1111/ejh.13604. 2021

Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant IDH2 (m IDH2) Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy (IC)

DiNardo, Courtney D.; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2021-147601. 2021

Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML).

Dinardo, Courtney Denton; (...); De Botton, Stephane

Meeting Abstract. 2022

Hematologic improvements with ivosidenib plus azacitidine compared to placebo plus azacitidine in patients with newly diagnosed acute myeloid leukemia.

Dohner, Hartmut; (...); De Botton, Stephane

Meeting Abstract. 2022

Hematopoietic Stem cell transplant in Aplastic anemia in patients older than 40 years: The experience of the Spanish Group of Hematopoietic Stem Cell Transplant (GETH)

Yanez, Lucrecia; (...); Solano, Carlos

Meeting Abstract. 2018

Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission.

Sanz, Jaime; (...); Marrow Transplantation (EBMT)

Article. 10.1038/s41409-020-01162-0. 2020

High Heterogeneity of Multidrug-Resistant Enterobacteriaceae Fecal Levels in Hospitalized Patients Is Partially Driven by Intravenous $\beta$-Lactams.

Djukovic, Ana; (...); Ubeda, Carles

Article. 2020

High heterogeneity of multidrug-resistant Enterobacteriaceae fecal levels in hospitalized patients is partially driven by intravenous beta-lactams.

Djukovic A; (...); Ubeda C

Article. 10.1128/AAC.01415-19. 2020

High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients despite thrombo-prophylaxis.

El-Qutob D; (...); Carrera-Hueso FJ

Article. 10.1016/j.hrtlng.2022.02.003. 2022

High-permeability region size on perfusion CT predicts hemorrhagic transformation after intravenous thrombolysis in stroke

Puig, J; (...); Castellanos, M

Article. 10.1371/journal.pone.0188238. 2017

Hospital pharmacy initiatives for improving the management of patients with congenital coagulopathies

Bruno Montoro-Ronsano, Jose; (...); Alberto Vella, Vincenzo

Article. 10.7399/fh.11729. 2022

Hospitalization budget impact during the COVID-19 pandemic in Spain.

Carrera-Hueso, F. J.; (...); Crespo-Palomo, C.

Article. 10.1186/s13561-021-00340-0. 2021

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.

Stahl M; (...); Zeidan AM

Article. 10.1182/bloodadvances.2018016121. 2018

Iadademstat in Combination with Azacitidine Generates Robust and Long Lasting Responses in AML Patients (ALICE Trial)

Salamero, Olga; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2021-152183. 2021

Idasanutlin Plus Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia: Results of the MIRROS Trial.

Konopleva, Marina Y.; (...); Wei, Andrew H.

Article. 10.1182/bloodadvances.2021006303. 2022

IDH1-mutated relapsed or refractory AML: current challenges and future prospects

Review. 10.2147/BLCTT.S177913. 2019

Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1080/10428194.2016.1231405. 2017

Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart (R) in patients with multiple sclerosis

Edo Solsona MD; (...); Poveda Andrés JL

Article. 10.2147/PPA.S127508. 2017

IMPACT OF ADHERENCE ON SUBCUTANEOUS INTERFERON BETA-1A EFFECTIVENESS ADMINISTERED BY REBISMART (R) IN PATIENTS WITH MULTIPLE SCLEROSIS

Edo-Solsona, M.; (...); Poveda-Andres, J.

Meeting Abstract. 10.1016/j.jval.2016.09.512. 2016

IMPACT OF ALLELIC STATUS OF TP53 MUTATIONS IN ACUTE MYELOID LEUKEMIA (AML)

Ibanez, Mariam; (...); Sanz, Guillermo

Meeting Abstract. 2020

Impact of an antimicrobial stewardship program on critical haematological patients.

Ruiz-Ramos, J; (...); Ramirez, P

Article. 10.7399/fh.2017.41.4.10709. 2017

Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.

Article. 10.1080/10428194.2020.1839650. 2020

Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study

Matteuzzi, Tommaso; (...); Bullinger, Lars

Meeting Abstract. 10.1182/blood-2021-152215. 2021

Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An Analysis from a Large International Patient Cohort

Stahl, M; (...); Zeidan, AM

Meeting Abstract. 10.1182/blood-2018-99-112495. 2018

Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia.

Paiva B; (...); PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) coop

Article. 10.1038/s41375-021-01126-3. 2021

Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1038/tpj.2017.19. 2018

Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1097/FPC.0000000000000286. 2017

Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019

Badia X; (...); Hernández C

Article. 10.1186/s13023-020-01507-4. 2020

IMPACT OF THE TREATMENT OF THE PURE APLASIA OF THE RED SERIES; EXPERIENCE IN A CENTER

Marco, Ayala Javier; (...); Solves, Alcaina Pilar

Meeting Abstract. 2020

Impact of voriconazole plasma concentrations on treatment response in critically ill patients

Ruiz, J; (...); Ramirez, P

Article. 10.1111/jcpt.12817. 2019

Implementation and results of a risk-sharing scheme for enzyme replacement therapy in lysosomal storage diseases

Edo-Solsona, MD, Vitoria-Minana, I, Poveda-Andres, JL

Article. 10.7399/fh.11262. 2020

IMPLEMENTATION OF MASSIVE SEQUENCING TECHNOLOGIES TO THE DETECTION OF MUTATIONS IN THE ABL KINASE DOMAIN OF BCR-ABL REORDERING

Simarro, CS; (...); Gonzalez, EB

Meeting Abstract. 2017

Implication of Haemodiafiltration Flow Rate on Amikacin Pharmacokinetic Parameters in Critically Ill Patients

Ruiz-Ramos, J; (...); Ramirez, P

Article. 10.1159/000478969. 2018

Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity.

Onecha E; (...); Ayala R

Article. 10.1111/bjh.16432. 2020

Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group

Ribera, Josep-Maria; (...); Feliu, Evarist

Article. 10.1002/cncr.32156. 2019

Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis.

Rodríguez-Veiga R; (...); Sanz GF

Article. 10.1007/s00277-019-03744-5. 2019

Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients

Pinana, JL; (...); Navarro, D

Article. 10.1111/tid.13158. 2019

Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials

Barba, P; (...); Ribera, JM

Article. 10.1111/ejh.13178. 2019

Individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A

Vericat, JEM; (...); Bonanad, S

Meeting Abstract. 2018

Individualized Prophylactic Treatment with Recombinant Factor VIII in Severe or Moderate Haemophilia a Patients. Association Between Pharmacokinetic Parameters and Clinical Variables

Megias-Vericat, Juan Eduardo; (...); Bonanad, Santiago

Meeting Abstract. 10.1182/blood.V128.22.3802.3802. 2016

Infections of the Central Nervous System after Untelated Donor Umbilical Cord Blood Transplantation or Human teukocyte Antigen-Matched Sibling Transplantation

Balaguer Rosello A; (...); Sanz, J

Article. 10.1016/j.bbmt.2016.10.005. 2017

Influence of concomitant immunomodulators during maintenance therapy with Adalimumab in inflammatory bowel disease: looking for the ideal patient to use monotherapy

Bastida, G; (...); Nos, P

Meeting Abstract. 10.1093/ecco-jcc/jjy222.581. 2019

Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1080/10428194.2017.1323267. 2017

Influence of pharmacokinetic/pharmacodynamic ratio on vancomycin treatment response in paediatric patients with Staphylococcus aureus bacteremia.

Ruiz J; (...); Poveda JL

Article. 10.23736/S0026-4946.18.04978-2. 2018

Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.

Article. 10.1097/FPC.0000000000000431. 2021

Influence of Polymorphisms Related to Drug Metabolism in Allogeneic Bone Marrow Transplantation

Santiago, M; (...); Alino, S

Meeting Abstract. 2021

Infusion of Haploidentical Stem Cell after Consolidation in Younger Patients with Acute Myeloid Leukemia: Preliminary Results of a Phase I-II Study

Boluda, Blanca; (...); Sanz, Miguel A.

Meeting Abstract. 10.1182/blood.V128.22.1614.1614. 2016

INHIBITORS OF THE MUTATED DEHYDROGENASE (MIDH), IVOSIDENIB OR ENASIDENIB, IN COMBINATION WITH AZACITINE (AZA) IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)

Montesinos, P; (...); Vyas, P

Meeting Abstract. 2018

INTENSIVE CHEMOTHERAPY VERSUS DECITABINE FIRST LINE LAM OVER 60 YEARS OLD

De la Fuente, A.; (...); Montesinos, P.

Meeting Abstract. 2019

Interdisciplinary recommendations document to improve adherence in patients with chronic inflammatory diseases: Adhing recommendations.

Bermejo San José F; (...); Sanromán-Álvarez L

Article. 10.7399/fh.2016.40.5.10180. 2016

Intraperitoneal vancomycin in neonates during peritoneal dialysis: A case report

Company-Albir, MJ; (...); Poveda, JL

Article. 10.1111/jcpt.12842. 2019

Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol.

Solana-Altabella A; (...); Poveda JL

Article. 10.1177/1078155220904410. 2020

Invasive fungal disease in patients undergoing umbilical cord blood transplantation after myeloablative conditioning regimen

Montoro, J; (...); Pinana, JL

Article. 10.1111/ejh.13202. 2019

INVASIVE FUNGAL INFECTION IN ADULT PATIENTS SUBMITTED TO UMBILICAL CORD BLOOD TRANSPLANTATION

Montoro, J.; (...); Pinana, J. L.

Meeting Abstract. 2018

Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19

Palanques-Pastor, T, Lopez-Briz, E, Andres, JLP

Article. 10.1136/ejhpharm-2020-002322. 2020

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.

Montesinos, Pau; (...); Dohner, Hartmut

Article. 10.1056/NEJMoa2117344. 2022

Ivosidenib and Azacitidine in IDH1-Mutated AML. Reply.

Montesinos, Pau, de Botton, Stephane, Dohner, Hartmut

Letter. 10.1056/NEJMc2206489. 2022

Kinetics of Torque Teno virus DNA in stools may predict occurrence of acute intestinal graft versus host disease early after allogeneic hematopoietic stem cell transplantation.

Bueno F; (...); Navarro D

Article. 10.1111/tid.13507. 2020

Lineage switch from B lymphoblastic leukemia with KMT2A-rearranged to mixed-phenotype acute leukemia under daratumumab

Marco-Ayala, J; (...); Peris, MLS

Editorial Material. 10.5045/br.2020.2020059. 2020

Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy

Martínez-Cuadrón D; (...); Sanz MA

Article. 10.1038/leu.2017.178. 2018

Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study

Rodriguez-Arboli, E; (...); GETH Grp Espanol Trasplante Hemato

Article. 10.1016/j.jtct.2020.12.029. 2021

Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries.

Recher, Christian; (...); Montesinos, Pau

Article. 10.1038/s41375-021-01425-9. 2022

Long-term survival of CML patients who received autologous HCT before and after the tyrosine kinase inhibitors ERA. Study on behalf of the EBMT CMWP

Michallet, M; (...); Yakoub-Agha, I

Meeting Abstract. 2019

Low-Dose Cytarabine With or Without Glasdegib in Newly Diagnosed Patients with Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial

Papayannidis, C; (...); Cortes, JE

Meeting Abstract. 10.1016/j.clml.2019.07.111. 2019

Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid leukemia: Long-term analysis of a phase 2 randomized trial.

Smith, BD; (...); Cortes, JE

Meeting Abstract. 2019

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

Sanz, MA; (...); Lo-Coco, F

Article. 10.1182/blood-2019-01-894980. 2019

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial

Ravandi, F; (...); Dombret, H

Article. 10.1186/s13045-021-01142-x. 2021

Management of flexible cavovarus foot in patients with Charcot-Marie-Tooth disease: midterm results.

Megías-Vericat JE; (...); Poveda-Andrés JL

Article. 2021

Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study.

Stahl M; (...); Zeidan AM

Article. 10.1038/s41375-020-0783-3. 2020

Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation.

Brissot E; (...); Mohty M

Article. 10.1038/s41409-020-0970-x. 2020

MASS SEQUENCING DIRECTED TO THE STUDY OF REARRANGEMENTS AND CHANGES IN GENIC EXPRESSION IN ACUTE MYELOID LEUKEMIA

Sargas Simarro, C.; (...); Barragan Gonzalez, E.

Meeting Abstract. 2019

Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A

Bonanad, S; (...); Santos, S

Article. 10.1007/s12325-021-01853-0. 2021

Measurable Residual Disease (MRD) Testing for Acute Leukemia in EBMT Transplant Centers: A Survey on Behalf of The ALWP of the EBMT

Nagler, A; (...); Mohty, M

Meeting Abstract. 2020

Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT.

Nagler, Arnon; (...); Mohty, Mohamad

Article. 10.1038/s41409-020-01005-y. 2021

Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial.

Simoes C; (...); Montesinos P

Article. 10.1182/bloodadvances.2020003195. 2021

Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches.

Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor

Article. 10.3390/cancers14030596. 2022

Metyrapone as treatment in the neonatal McCune-Albright syndrome

de Mingo, Carmen; (...); Garcia-Robles, Ana

Article. 10.1515/jpem-2020-0036. 2020

MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine +/- idasanutlin in relapsed or refractory acute myeloid leukemia

Montesinos, P; (...); Fenaux, P

Article. 10.2217/fon-2020-0044. 2020

MIRROS: An ongoing randomized phase 3 trial of idasanutlin plus ARA-C in patients with relapsed or refractory acute myeloid leukemia.

Montesinos, P; (...); Fenaux, P

Meeting Abstract. 2019

MODELING OF IDH2 GENE MUTATIONS IN THE CAENORHABDITIS ELEGANS ORGANISM. DEVELOPMENT OF A NEW STUDY MODEL

Gonzalez-Romero, E.; (...); Cervera-Zamora, J.

Meeting Abstract. 2021

Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH(1) Acute Myeloid Leukemia

De Botton, Stephane; (...); Fenaux, Pierre

Meeting Abstract. 10.1182/blood-2021-144912. 2021

MOLECULAR CHARACTERIZATION OF ACUTE LEUKAEMIA OF CHILD, ADOLESCENT AND YOUNG ADULT THROUGH MASSIVE GUIDED SEQUENCING

Llop Garcia, M.; (...); Barragan Gonzalez, E.

Meeting Abstract. 2019

Molecular characterization of clinical response in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib plus azacitidine compared to placebo plus azacitidine.

De Botton, Stephane; (...); Dohner, Hartmut

Meeting Abstract. 2022

Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.

Ribera J; (...); Ribera JM

Article. 10.1002/gcc.22788. 2019

Monitoring coagulation factors during surgery. A systematic review

Eduardo Megias-Vericat, Juan; (...); Luis Poveda-Andres, Jose

Review. 10.7399/fh.11766. 2021

Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH).

Valero-García S; (...); Delgado-Sánchez O

Article. 10.7399/fh.11655. 2021

MONITORING MINIMUM RESIDUAL DISEASE (EMR) THROUGH NGS CONFIRMS PROGNOSTIC VALUE

De La Fuente, EO; (...); Diaz, RA

Meeting Abstract. 2018

Monitoring the quality of the hospital pharmacoterapeutic process by sentinel patient program.

Fernandez-Megia, MJ; (...); Poveda Andrés JL

Article. 10.7399/fh.10793. 2018

Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3(mut+)) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort

Esteve, J; (...); Bahceci, E

Meeting Abstract. 10.1182/blood-2018-99-110976. 2018

Multicentre Implementation of Next Generation Sequencing to Acute Myeloid Leukemia Patients in PETHEMA Spanish Collaborative Group

Sargas, C; (...); Barragan, E

Meeting Abstract. 2019

Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments

Gomez-Cebrian, N; (...); Pineda-Lucena, A

Review. 10.3390/cancers13184544. 2021

Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML).

Dinardo, CD; (...); Vyas, P

Meeting Abstract. 10.1200/JCO.2018.36.15_suppl.7042. 2018

Mutational profile of ZBTB16-RARA-positive acute myeloid leukemia

Fabiani E; (...); Voso MT

Article. 10.1002/cam4.3904. 2021

Myeloablative Unrelated Cord Blood Transplantation in Adolescents and Young Adults with Acute Leukemia.

Hayashi H; (...); Eurocord, Cellular Therapy & Immunobiology Working Party, and Paediatric Disease

Article. 10.1016/j.bbmt.2019.07.031. 2019

NATIONAL EXPERIENCE WITH THE USE OF VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Labrador, J.; (...); Montesinos, P.

Meeting Abstract. 2020

National Survey of the SEFH-2019: portfolio of services, healthcare activity, teaching and research in Hospital Pharmacy Services in Spain (vol 45, pg 32, 2021)

Perez-Encinas, Montserrat; (...); Angel Calleja-Hernandez, Miguel

Correction. 10.7399/fh.11740. 2021

Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project.

Sargas C; (...); Montesinos P

Article. 10.3324/haematol.2020.263806. 2021

NEW MODEL TO QUANTIFY THE IN VITRO PHARMACOLOGICAL ACTIVITY OF BI-SPECIFIC ANTIBODIES IN HAEMATOLOGIC MALIGNANCIES

Primo, D.; (...); Ballesteros, J.

Meeting Abstract. 2017

NGS ANALYSIS IN ADULTS GREATER THAN 65 YEARS DIAGNOSED OF ACUTE MYELOID LEUKEMIA IN LOW INTENSITY TREATMENTS

Garcia, AB; (...); Lopez, JM

Meeting Abstract. 2017

Nicord Single Unit Expanded Umbilical Cord Blood Transplantation (UCBT): Final Results of a Multicenter Phase I/II Trial

Horwitz, ME; (...); Sanz, G

Meeting Abstract. 10.1016/j.bbmt.2017.12.628. 2018

No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.

Castano-Bonilla, Tamara; (...); Montesinos, Pau

Article. 10.1155/2022/3132941. 2022

Noninfectious Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation

Balaguer-Rosello, A; (...); Sanz, Jaime

Article. 10.1016/j.bbmt.2019.05.024. 2019

Non-infectious neurologic complications after allogeneic hematopoietic stem cell transplantation (ALLO-HSCT)

Balaguer Rosello, Aitana; (...); Sanz, Jaime

Meeting Abstract. 2019

Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT.

Nagler, Arnon; (...); Mohty, Mohamad

Article. 10.1038/s41409-021-01537-x. 2022

Non-T Depleted Haploidentical Stem Cell Transplantation in Aml Patients Achieving First Complete Remission After One Vs Two Induction Courses: A Study From The ALWP/EBMT

Nagler, A; (...); Mohty, M

Meeting Abstract. 2021

Obesity is a risk factor for acute promyelocytic leukemia: evidence from population and cross-sectional studies studies and correlation with flt3 mutations and polyunsaturated fatty acid metabolism.

Mazzarella L; (...); Pelicci PG

Article. 10.3324/haematol.2019.223925. 2020

OBSERVATIONAL CLINICAL TRIAL FOR THE VALIDATION OF A TEST OF PRECISION MEDICINE IN ACUTE MYELOID LEUKEMIA

Montesinos, P.; (...); Sanz, M.

Meeting Abstract. 2017

Ofatumumab as Part of Reduced Intensity Conditioning in High Risk b-cell Lymphoma Patients: Results from a Prospective Multicenter Phase-II Trial

Cabrero, M; (...); Caballero, D

Meeting Abstract. 2020

Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia

Cortes, Jorge E.; (...); Wei, Andrew H.

Meeting Abstract. 10.1182/blood-2021-144905. 2021

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Watts, Justin M.; (...); Cortes, Jorge E.

Meeting Abstract. 10.1182/blood-2019-123920. 2019

One or two umbilical cord blood cell units? Caveat emptor

Sanz J, Gale RP

Article. 10.1038/bmt.2016.277. 2017

Online course of pharmacokinetic monitoring in hemophilia with application in the clinical practice

Bonanad, S; (...); Poveda, JL

Meeting Abstract. 2018

Optimizing Outcomes of Acute Leukemia After Transplants with Single Unrelated Cord Blood Units Selected According to Current International Recommendations for Cell Dose and HLA Match

Rafii, H; (...); Gluckman, E

Meeting Abstract. 2020

Oral Azacitidine (Oral-AZA) improves Overall Survival (OS) and Relapse-free Survival (RFS) for patients with Acute Myeloid Leukemia (AML) in first remission after Intensive Chemotherapy (IC), regardless of amount of consolidation received: Results of the QUAZAR AML-001 maintenance trial

Dohner, H.; (...); Ravandi, F.

Meeting Abstract. 2021

Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukaemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial

Wei, Andrew; (...); Roboz, Gail

Meeting Abstract. 2022

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.

Wei AH; (...); Roboz GJ

Article. 10.1056/NEJMoa2004444. 2020

Outcome of a Real-Life Population of Patients With Acute Promyelocytic Leukemia Treated According to the PETHEMA Guidelines: The Polish Adult Leukemia Group (PALG) Experience.

Sobas M; (...); Giebel S

Article. 10.1016/j.clml.2019.09.616. 2020

Outcome of Acute Myeloid Leukemia with Inv(3)(Q21q26.2)/ T(3;3)(Q21;Q26.2). Experience of the Spanish PETHEMA and CETLAM Groups

Sitges, M; (...); CETLAM Cooperative Grp

Meeting Abstract. 2019

Outcome of older (=70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study.

Kayser S; (...); Montesinos P

Article. 10.1038/s41375-020-0758-4. 2020

Outcome of older (>= 70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study (vol 34, pg 2333, 2020)

Kayser, Sabine; (...); Montesinos, Pau

Correction. 10.1038/s41375-021-01358-3. 2021

Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials

Ribera, JM; (...); PETHEMA Grp

Article. 10.1002/hon.2910. 2021

Outcomes for Patients with Late-Stage Mutant-IDH2 (m IDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify Trial

DiNardo, Courtney D.; (...); de Botton, Stephane

Meeting Abstract. 10.1182/blood-2021-147593. 2021

Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis Who Did Not Undergo Intensive Chemotherapy: Results from a Large International Database

Shallis, RM; (...); Zeidan, AM

Meeting Abstract. 10.1182/blood-2018-99-119755. 2018

Overactivation of the NLRP3 Inflammasome in Chronic Myelomonocytic Leukemia KRAS Mutated Patients Can be Detected By the Apoptosis- Associated Speck-like Protein (ASC) and Reverted By IL1 beta Inhibitors

Hurtado-Navarro, Laura; (...); Marin, Francisca Ferrer

Meeting Abstract. 10.1182/blood-2021-153686. 2021

Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol

Garcia-Robles, Ana; (...); Carrascosa, MA

Article. 10.3389/fped.2020.00372. 2020

Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol (vol 8, 372, 2020)

Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta

Correction. 10.3389/fped.2021.834454. 2022

Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia.

Sanz J; (...); Piñana JL

Article. 10.1016/j.bbmt.2019.08.020. 2020

Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project

Morillo-Verdugo, R; (...); Diaz-Olmo, J

Article. 10.7399/fh.11719. 2021

Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project.

Morillo-Verdugo R; (...); Díaz-Olmo J

Article. 2021

Patient Reported Outcomes in Patients with Newly Diagnosed FLT3(mut+) acute Myeloid Leukemia Ineligible for Intensive Induction Chemotherapy from Lacewing: A Randomized Phase 3 Trial of Gilteritinib and Azacitidine Versus Azacitidine Alone

Wang, Eunice S.; (...); Shah, Manasee V.

Meeting Abstract. 10.1182/blood-2021-144977. 2021

Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study

Rodriguez-Medina, C; (...); Fernandez, PM

Article. 10.1016/j.leukres.2020.106352. 2020

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia

Stahl, M; (...); Zeidan, AM

Letter. 10.1080/10428194.2018.1468893. 2019

Personalized Survival Prediction of Patients With Acute Myeloblastic Leukemia Using Gene Expression Profiling

Orgueira, AM; (...); Lopez, JLB

Article. 10.3389/fonc.2021.657191. 2021

Pharmaceutical care to hospital outpatients during the COVID-19 pandemic. Telepharmacy

Margusino-Framiñán L; (...); Morillo-Verdugo R

Article. 10.7399/fh.11498. 2020

Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia

Review. 10.2174/1389200218666171101124931. 2018

Pharmacogenomics and the treatment of acute myeloid leukemia

Megías-Vericat JE; (...); Aliño SF

Review. 10.2217/pgs-2016-0055. 2016

Pharmacologic evaluation of bispecific antibodies: A novel method to quantify their in vitro activity in hematologic samples.

Primo, D; (...); Ballesteros, J

Meeting Abstract. 2017

Pharmacometabolomics by NMR in Oncology: A Systematic Review.

Gómez-Cebrián N; (...); Pineda-Lucena A

Article. 10.3390/ph14101015. 2021

Pharmacotherapeutic management of advanced therapy medicinal products

Luis Poveda-Andres, Jose; (...); Valero-Garcia, Silvia

Article. 10.7399/fh.13036. 2022

Pharmacotherapy follow-up of patients under treatment with biologic agents for chronic inflammatory systemic conditions: an agreement among hospital pharmacists for the standardized collection of a minimum set of data.

Calleja Hernández MÁ; (...); Aragon, B

Article. 10.7399/fh.2017.41.1.10463. 2017

Phase 1 study of LP-108 as monotherapy and in combination with azacitidine in patients with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).

Walker, Alison R.; (...); William Burke, Patrick

Meeting Abstract. 2022

Phase 1/2 study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in patients with IDH1/2-mutated acute myeloid leukemia: The DIAMOND-01 trial.

Martinelli, Giovanni; (...); Montesinos, Pau

Meeting Abstract. 2022

Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy

Wang, Eunice S.; (...); Tiu, Ramon V.

Meeting Abstract. 10.1182/blood-2021-145379. 2021

Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide

Horwitz, ME; (...); Sanz, G

Article. 10.1200/JCO.18.00053. 2019

Physical Activity In Haemophilia: Hemorrhagic Risk And Factor Levels (myPKFiT)

Querol-Fuentes, F; (...); Bonanad, S

Meeting Abstract. 2017

Pilot evaluation of home delivery programme in haemophilia

Megias-Vericat, JE; (...); Poveda-Andres, JL

Article. 10.1111/jcpt.12718. 2018

PK-GUIDED SWITCH BETWEEN STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII PRODUCTS

Vericat, JEM; (...); Iorio, A

Meeting Abstract. 2020

PLZF-RAR(alpha), NPM1-RAR(alpha), and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature Review

Sobas, M; (...); Montesinos, P

Review. 10.3390/cancers12051313. 2020

PONATINIB AND CHEMOTHERAPY IN YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA WITH PHILADELPHIA CHROMOSOME. RESULTS OF THE PONALFIL CLINICAL TRIAL WITH COMPLETE RECRUITMENT

Ribera, J. M.; (...); Garcia-Sanz, R.

Meeting Abstract. 2020

PONATINIB AND CHEMOTHERAPY IN YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WITH PHILADELPHIA CHROMOSOME. PRELIMINARY RESULTS OF THE PONALFIL CLINICAL TRIAL

Ribera Santasusana, J. M.; (...); Garcia-Sanz, R.

Meeting Abstract. 2019

PONATINIB AND CHEMOTHERAPY IN YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WITH PHILADELPHIC CHROMOSOME (LAL PH plus ). RESULTS OF THE PONALFIL CLINICAL TRIAL WITH MEDIUM 2-YEAR FOLLOW-UP

Ribera Santasusana, J. M.; (...); Garcia-Sanz, R.

Meeting Abstract. 2021

Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblstic Leukemia. Preliminary Results of Ponalfil Clinical Trial

Ribera, Josep-Maria; (...); Garcia-Sanz, Ramon

Meeting Abstract. 10.1182/blood-2019-125558. 2019

Ponatinib, Chemotherapy, and Transplant in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

Ribera, Josep-Maria; (...); Garcia-Sanz, Ramon

Article. 10.1182/bloodadvances.2022007764. 2022

Post-transplant cyclophosphamide after HLA identical compared to Haploidentical donor transplant in Acute Myeloid Leukemia: a study on behalf of GETH-TC.

Bailen, Rebeca; (...); Kwon, Mi

Article. 10.1016/j.jtct.2022.01.020. 2022

Post-Transplant Cyclophosphamide after HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of Geth-TC

Bailen, Rebeca; (...); Kwon, Mi

Meeting Abstract. 10.1182/blood-2021-150835. 2021

Post-transplant Cyclophosphamide after Matched Sibling and Matched Unrelated Compared to Haploidentical Donor Transplants in Patients with Acute Myeloid Leukemia, a Study on Behalf of Geth

Kwon, M; (...); Martin, JLD

Meeting Abstract. 2020

Post-Transplant Cyclophosphamide after Matched Sibling, Unrelated and Haploidentical Donor Transplants in Patients with Acute Myeloid Leukemia, a Comparative Study of the ALWP EBMT

Sanz, Jaime; (...); Nagler, Arnon

Meeting Abstract. 10.1182/blood-2019-125859. 2019

Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT.

Sanz J; (...); Acute Leukemia Working Party of the European Society for Blood and Marrow Transp

Article. 10.1186/s13045-020-00882-6. 2020

Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia.

Lazzari, Lorenzo; (...); Sanz, Jaime

Article. 10.1038/s41409-022-01725-3. 2022

Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT

Sanz, J; (...); Mohty, M

Article. 10.1186/s13045-021-01094-2. 2021

Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation.

Bailén R; (...); Díez-Martín JL

Article. 10.1007/s00277-020-04317-7. 2020

Post-transplant cyclophosphamide for GVHD prophylaxis in matched unrelated donor transplantation

Bailen, R; (...); Kwon, M

Meeting Abstract. 2019

Post-Transplant Cyclophosphamide for Gvhd Prophylaxis in Matched Unrelated Donor Transplantation Compared to ATG-Based Prophylaxis

Bailen, Rebeca; (...); Luis Diez-Martin, Jose

Meeting Abstract. 10.1182/blood-2019-124849. 2019

Post-Transplant Cyclophosphamide in Acute Leukemia Patients Receiving More Than 5/10 HLA-Mismatched Allogeneic Stem Cell Transplantation: A Study on Behalf of the ALWP of the EBMT

Wieczorek, Michele; (...); Mohty, Mohamad

Meeting Abstract. 10.1182/blood-2021-151087. 2021

Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors

Brissot, E; (...); Mohty, M

Article. 10.1186/s13045-020-00923-0. 2020

Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.

Romero S; (...); Sanz J

Article. 10.1080/10428194.2018.1474462. 2019

Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

Sahebi, Firoozeh; (...); Schonland, Stefan

Article. 10.1016/j.jtct.2021.09.008. 2021

Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports.

Martínez-Cuadrón D; (...); Montesinos P

Article. 10.1007/s40261-019-00881-7. 2020

Pre and post intervention study of antiblastic drugs contamination surface levels at a Pharmacy Department Compounding Area using a closed system drug transfer device and a decontamination process

Valero, S; (...); Poveda, JL

Article. 10.1016/j.yrtph.2018.03.001. 2018

Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?

Review. 10.1080/17474086.2020.1818559. 2020

Precision Medicine Test Is Similar but Faster Than Conventional Cytogenetics Predicting Response in AML Patients and Provides Alternative Treatments

Ballesteros, J; (...); Montesinos, P

Meeting Abstract. 10.1182/blood-2018-99-115849. 2018

Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy

Abla, O; (...); Sanz, MA

Article. 10.1007/s00277-017-3042-6. 2017

PRELIMINAR STUDY OF THERAPY ADHERENCE CONTROLLED BY PRESCRIPTION OF MEDICATION AND SELF-PERCEPTION ADHERENCE OF INFLAMMATORY CHRONIC DISEASE PATIENTS

Garcia, EG; (...); Ivorra, JAR

Meeting Abstract. 10.1136/annrheumdis-2019-eular.5937. 2019

Preparación y administración de perfusiones de insulina en neonatología: Encuesta nacional.

García-Robles A; (...); Aguar-Carrascosa M

Letter. 10.1016/j.anpedi.2020.06.008. 2021

Preparation and administration of insulin infusions in neonatology: A national survey.

Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta

Article. 10.1016/j.anpede.2020.06.015. 2021

Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia.

Cortes JE; (...); Wang ES

Review. 10.1186/s13045-020-00975-2. 2020

Proactive therapeutic drug monitoring and pharmacogenetic analysis in inflammatory bowel disease: A systematic review

Ballesta-Lopez, Octavio; (...); Luis Poveda-Andres, Jose

Review. 10.7399/fh.11780. 2021

Prognosis and Survival of Acute Myeloid Leukemia: Experience of a Single Center in Colombia

Sossa, CL; (...); Jimenez, SI

Meeting Abstract. 10.1182/blood-2018-99-119927. 2018

Prognosis Value of Measurable Residual Disease By Multiparameter Flow Cytotometry in Patients with Acute Myeloblastic Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation

Caballero, Teresa; (...); Perez-Simon, Jose A.

Meeting Abstract. 10.1182/blood-2021-151533. 2021

PROGNOSIS VALUE OF MINIMAL DETECTABLE DISEASE (MDD) BY 2(nd) GENERATION ALLOGENIC PRE-TRANSPLANTATION CYTOMETRY IN PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIA

Velazquez Teresa, Caballero; (...); Jose Antonio, Perez Simon

Meeting Abstract. 2021

Prognostic factors of overall (OS) and relapse-free survival (RFS) for patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy (IC): Multivariate analyses from the QUAZAR AML-001 trial of oral azacitidine (Oral-AZA).

Roboz, Gail J.; (...); Dohner, Hartmut

Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.7014. 2021

Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance

Dohner, Hartmut; (...); de Menezes, Daniel Lopes

Meeting Abstract. 10.1182/blood-2021-147465. 2021

Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens.

Castaño-Bonilla T; (...); Montesinos, P

Article. 10.1038/s41598-021-00050-x. 2021

PROPOSED MOLECULAR CLASSIFICATION OF ACUTE MYELOBLASTIC LEUKEMIA (AML) BASED ON SPLICING EVENTS

Liquori, A.; (...); Cervera Zamora, J.

Meeting Abstract. 2021

Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies.

Sanz J; (...); Piñana JL

Article. 10.1016/j.bbmt.2019.10.014. 2020

Prostaglandin Injection After Arterial Compromise Related to Hyaluronic Acid Filler

Sanz, Jaime, Montesinos, Pau, Sanz, Miguel A

Letter. 10.1097/DSS.0000000000001046. 2017

Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia

Pinana, JL; (...); Navarro, D

Article. 10.1016/j.jinf.2019.02.009. 2019

Pulmonary invasive fungal disease after community acquire respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients: Results from a prospective observational study

Pinana, Jose; (...); Navarro, David

Meeting Abstract. 2019

Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question.

Marco-Ayala J; (...); Solves P

Review. 10.1038/s41409-020-01124-6. 2021

Quantification of physical activity in adult patients with haemophilic arthropathy in prophylaxis treatment using a fitness tracker

Perez-Alenda, S; (...); Querol, F

Letter. 10.1111/hae.13388. 2018

QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML)

Schlenk, R; (...); Erba, H

Meeting Abstract. 2017

QuANTUM-R: phase 3, randomised trial of Quizartinib in patients with FLT3-Internal tandem duplication (FLT3-ITD)-positive relapsed/refractory (R/R) acute myeloid meukaemia (AML)

Radsak, M. P.; (...); Levis, M. J.

Meeting Abstract. 2019

Quizartinib in FLT3-ITD-Mutated Relapsed/Refractory Acute Myeloid Leukemia: QuANTUM-R Trial Results

Cortes, JE; (...); Levis, MJ

Meeting Abstract. 10.1093/annonc/mdz374.003. 2019

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

Cortes, JE; (...); Levis, MJ

Article. 10.1016/S1470-2045(19)30150-0. 2019

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

Cortes, JE; (...); Heuser, M

Article. 10.1038/s41375-018-0312-9. 2019

Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA plus )

Falantes, J; (...); European ALMA?+?Investigators

Article. 10.1080/10428194.2017.1365854. 2018

Real life outcomes of patients aged =75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry.

Salamero O; (...); PETHEMA and PALG Groups

Article. 10.1080/10428194.2019.1607327. 2019

Real-Life Evidence of Treatment with Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Saiz-Rodriguez, M; (...); Pethema Grp

Meeting Abstract. 2021

REAL-LIFE EVIDENCE OF VENETOCLAX TREATMENT IN PATIENTS WITH ACUTE REPLAPSE OR REFRACTORY LEUKEMIA MYELOID

Jorge, Labrador; (...); Pau, Montesinos

Meeting Abstract. 2021

Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients.

Spyridonidis A; (...); Mohty M

Article. 10.1038/s41409-020-0803-y. 2020

Reduced Intensity (RIC) vs Myeloablative Conditioning (MAC) in Cord Blood Transplantation for AML (40-60 Years) Across Mismatched HLA Barriers - Analysis by Ctiwp/eurocord of EBMT

Sheth, V; (...); Ruggeri, A

Meeting Abstract. 2020

Reduced-Intensity versus Myeloablative Conditioning in Cord Blood Transplantation for Acute Myeloid Leukemia (40-60 years) across Highly Mismatched HLA Barriers-On Behalf of Eurocord and the Cellular Therapy & Immunobiology Working Party (CTIWP) of EBMT.

Sheth V; (...); Ruggeri A

Article. 10.1016/j.bbmt.2020.07.025. 2020

Reduction in alert fatigue in an assisted electronic prescribing system, through the Lean Six Sigma methodology.

Cuéllar Monreal MJ; (...); Poveda Andrés JL

Article. 10.7399/fh.2017.41.1.10434. 2017

REMOVAL OF GERMINAL LINE MUTATIONS IN PATIENTS WITH MDS AND AML: WHO SHOULD BE PERFORMED?

Santiago, Marta; (...); Cervera, Jose

Meeting Abstract. 2020

RESCUE TREATMENT WITH DECITABINE AFTER PROGRESSION TO AZACITIDINE IN AML

De la Fuente, A; (...); Montesinos, P

Meeting Abstract. 2018

Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)

Kantarjian, Hagop M.; (...); Chiao, Judy H.

Article. 10.1002/cncr.33828. 2021

RESULTS OF HLA IDENTICAL ALLOGENIC TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS HAPLOIDENTIAL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: EXPERIENCE OF THE SPANISH HAEMATOPOIETIC TRANSPLANT GROUP (GETH)

Almorox Rebeca, Bailen; (...); Mi, Kwon

Meeting Abstract. 2021

RESULTS OF THE TREATMENT OF LYMPHOBLASTIC LYMPHOMA WITH PROTOCOLS OF LYMPHOBLASTIC ACUTE LEUKEMIA OF PETHEMA GROUP

Sagues, M.; (...); Ribera, J. M.

Meeting Abstract. 2019

Risk factors and outcomes of follicular lymphoma after allogeneic hematopoietic stem cell transplantation using HLA-matched sibling, unrelated, and haploidentical-related donors.

Montoro, Juan; (...); Pinana, Jose Luis

Letter. 10.1038/s41409-020-01161-1. 2020

Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients

Ribera, Josep-Maria; (...); Sancho, Juan-Manuel

Meeting Abstract. 10.1182/blood-2019-125683. 2019

Role of Hematopoietic Stem Cell Transplantation in Acute Promyelocytic Leukemia.

Review. 10.3389/fonc.2021.614215. 2021

Role of Measurable Residual Disease (MRD) in Redefining Complete Response (CR) in Elderly Patients with Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial

Paiva, B; (...); Montesinos, P

Meeting Abstract. 10.1182/blood-2018-99-113299. 2018

Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives.

Pinto-Merino, Alvaro; (...); Saiz-Rodriguez, Miriam

Article. 10.3390/pharmaceutics14030559. 2022

Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study.

Escamilla Gómez V; (...); Pérez-Simón JA

Article. 10.1038/s41409-019-0731-x. 2020

Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia

Daver, Naval; (...); Sweet, Kendra

Meeting Abstract. 10.1182/blood-2021-146503. 2021

Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.

Montesinos P; (...); Wei AH

Article. 10.1038/s41375-020-0773-5. 2020

Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review

Review. 10.1007/s00277-018-3304-y. 2018

Salvage therapy with topical posaconazole in lung transplant recipients with invasive Scedosporium infection.

Sole, A; (...); Peman, J

Article. 10.1111/ajt.14580. 2018

Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective.

Moles-Poveda, P; (...); Botella-Estrada, R

Article. 10.1016/j.ad.2017.11.003. 2018

SCREENING FOR POTENTIAL THERAPEUTIC OPPORTUNITIES FOR B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WITH IKZF1 DELETIONS

Ribera, Jordi; (...); Ribera, Josep Maria

Meeting Abstract. 2020

Seasonal human coronaviruses respiratory tract infection in recipients of allogeneic hematopoietic stem cell transplantation.

Piñana JL; (...); Infectious Diseases Working Party of the European Society for Blood and Marrow T

Article. 10.1093/infdis/jiaa553. 2020

Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia

Kharfan-Dabaja, MA; (...); Mohty, M

Article. 10.1111/bjh.17426. 2021

Secondary and Therapy-Related Acute Promyelocytic Leukemia. Experience of the PETHEMA Registry

Montesinos, P; (...); GATLA Cooperative Grp

Meeting Abstract. 2017

SEFH National Survey-2019: general characteristics, staffing, material resources and information systems in Spain's hospital pharmacy departments.

Pérez-Encinas M; (...); Calleja-Hernández MÁ

Article. 10.7399/fh.11565. 2020

SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial

Paoli, Alessandro; (...); Pellacani, Andrea

Meeting Abstract. 10.1182/blood-2021-150277. 2021

Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review.

Cortes JE; (...); Heuser M

Review. 10.1080/10428194.2020.1817445. 2020

Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice

Aguas Peris M; (...); Nos, P

Article. 10.1097/MIB.0000000000001182. 2017

Serum adalimumab levels predict successful remission and safe de-intensification in inflammatory bowel disease patients in clinical practice

Aguas, M; (...); Nos, P

Meeting Abstract. 2017

Should we seek complete liver tests normalization in primary biliary cholangitis? Data from ColHai registry

Diaz-Gonzalez, Alvaro; (...); del Registro, Grupo

Meeting Abstract. 2022

Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis.

Hernani, Rafael; (...); Solano, Carlos

Article. 10.1002/jha2.183. 2021

SMPTall man lettering application in medication information systems as a quality and safety strategy in hospital organization

Iglesias Gomez, Ruben; (...); Poveda Andres, Jose Luis

Article. 10.1111/jcpt.13703. 2022

Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients.

Pinana, JL; (...); Bosch F

Article. 10.1080/10428194.2021.1992619. 2021

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

Zeidan, AM; (...); Mascarenhas, J

Review. 10.1016/S2352-3026(20)30205-2. 2020

STUDY OF MUTATIONAL PROFILE AND CORRELATION OF RESPONSE TO EX VIVO PHARMACOLOGICAL TEST, IN THE DIAGNOSTIC OF THE AML

de la Fuente, EO; (...); Diaz, RA

Meeting Abstract. 2018

STUDY OF PRE-EXISTING MUTATIONS IN HEMATOPOYETIC CELLS OF THE BONE MEDULA IN PATIENTS WITH MYELOID NEOPLASIAS RELATED TO THERAPY

Ibanez, M; (...); Sanz, G

Meeting Abstract. 2017

STUDY OF THE EFFECTIVENESS OF IMATINIB IN CHRONIC GRAFT-VERSUS-HOST DISEASE IN A SERIES OF 19 CASES

Poveda, PM; (...); Caballer, JS

Meeting Abstract. 2017

STUDY OF TRANSCRIPTIONAL DIFFERENCES BETWEEN THE IDH2 R140 AND R172 MUTATIONS BY MEANS OF MODELING IN THE ORGANISM CAENORHABDITIS ELEGANS

Gonzalez, Romero Elisa; (...); Cervera, Jose Vicente

Meeting Abstract. 2020

Survival of Patients with Acute Myeloid Leukemia According to Age in a University Hospital in Colombia

Melo, CLS; (...); Montesinos, P

Meeting Abstract. 2021

Survival of Patients with Acute Myeloid Leukemia, Taken to Hematopoietic Stem Cell Transplantation: Experience of A Center in Colombia

Melo, CLS; (...); Ortiz, MF

Meeting Abstract. 2021

Survival of Patients with Secondary Acute Myeloid Leukemia in a University Hospital in Colombia

Ortiz, MF; (...); Sossa, C

Meeting Abstract. 2021

Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy

Cortes, JE; (...); Heuser, M

Article. 10.1186/s13045-020-00929-8. 2020

Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia

Review. 10.3390/pharmaceutics14040878. 2022

T lymphocytes as therapeutic arsenal for patients with hematological malignancies

Montoro, J; (...); Guerreiro, M

Review. 10.1097/CCO.0000000000000481. 2018

t(1;19)(q23;p13) TCF3-PBX1 May Not Be an Intermediate-Risk Subtype in Adult B-Cell Precursor Acute Lymphoblastic Leukemia Patients Treated With MRD-Oriented Protocols from the PETHEMA Group

Ribera, J; (...); Ribera, JM

Meeting Abstract. 2021

Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey

Pigneux, A; (...); Bruggemann, M

Article. 10.1186/s12885-018-5002-5. 2018

The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: a pilot trial from the GETH and GELLC (CLL4 trial)

Montesinos, P; (...); Delgado, J

Letter. 10.1038/bmt.2016.145. 2016

The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation.

Piñana J; (...); Sanz J

Article. 10.1016/j.jinf.2019.12.022. 2020

THE COMBINATION OF GENOMIC ANALYSIS AND MINIMAL RESIDUAL DISEASE IMPROVES THE STRATIFICATION OF ADULT PATIENTS WITH TYPE T-LYMPHOBLASTIC LEUKEMIA (LAL-T) TREATED ACCORDING TO THE PETHEMA PROTOCOLS

Gonzalez Gil, C.; (...); Genesca Ferrer, E.

Meeting Abstract. 2021

The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.

Gil-Nagel A; (...); Gil A

Article. 10.1016/j.yebeh.2022.108711. 2022

The Disease-Risk Stratification Scheme (DRSS), a Contemporary Risk-Stratification System for Allogeneic Stem Cell Transplantation.

Shouval R; (...); Nagler A

Meeting Abstract. 10.1182/blood-2019-123310. 2019

The effect of timing on community acquired respiratory virus infection mortality during the first year after allogeneic hematopoietic stem cell transplantation: a prospective epidemiological survey.

Piñana JL; (...); Navarro D

Article. 10.1038/s41409-019-0698-7. 2020

The First Real-World Evidence Prospective Registry of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Tagraxofusp, a CD123-Targeted Therapy, in Europe

Platzbecker, Uwe; (...); Mohty, Mohamad

Meeting Abstract. 10.1182/blood-2021-145099. 2021

The Impact of Cytogenetic Risk on Outcome of Non-T Cell Depleted Haploidentical Stem Cell Transplantation in Relapsed/Refractory AML: A Study From The ALWP/EBMT

Nagler, A; (...); Mohty, M

Meeting Abstract. 2021

The modular network structure of the mutational landscape of Acute Myeloid Leukemia

Ibanez, M; (...); Cervera, J

Article. 10.1371/journal.pone.0202926. 2018

The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial

Ayala, R; (...); Montesinos, P

Article. 10.3390/cancers13102458. 2021

The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients

Ribera, J; (...); Ribera, JM

Article. 10.1111/bjh.15887. 2019

The QUAZAR AML-001 maintenance trial: Results of a phase III international, randomized, double-blind, placebo-controlled study of oral CC-486 in patients with Acute Myeloid Leukemia (AML) in first remission

Dohner, H; (...); Roboz, GJ

Meeting Abstract. 2020

The view of experts on initiatives to be undertaken to promote equity in the access to orphan drugs and specialised care for rare diseases in Spain: A Delphi consensus

Torrent-Farnell, J; (...); Lizan, L

Article. 10.1016/j.healthpol.2018.03.002. 2018

Thiotepa-based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia-A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Eder, S; (...); Nagler, A

Article. 10.1002/ajh.24567. 2017

Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Eder S; (...); Nagler A

Article. 10.1002/ajh.24823. 2017

Time and Cost of Hospitalisation for Salvage Therapy in Adults with Philadelphia Chromosome-Negative B Cell Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in Spain

Boluda, B; (...); Montesinos, P

Article. 10.1007/s41669-018-0098-8. 2019

Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia.

Jonas, Brian A.; (...); Ofran, Yishai

Article. 10.1002/ajh.26600. 2022

Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimised dosing schedule.

Marques MR; (...); Mangas-Sanjuan V

Article. 10.1111/apa.14944. 2020

Towards a symbiotic relationship between big data, artificial intelligence, and hospital pharmacy

Del Rio-Bermudez, C; (...); Poveda, JL

Editorial Material. 10.1186/s40545-020-00276-6. 2020

TRANSCRIPTIONAL CHARACTERIZATION OF ACUTE MYELOID LEUKEMIA AT DIAGNOSIS IN THE ELDERLY PATIENT WITH IDENTIFICATION OF NEW PROGNOSTIC GROUPS

Sara, Villar; (...); Pau, Montesinos

Meeting Abstract. 2021

TRANSCRIPTOMICAL ANALYSIS AND MODELING IN C.ELEGANS OF THE IDH2 R140 R172 MUTATION

Gonzalez-Romero, E.; (...); Cervera-Zamora, J., V

Meeting Abstract. 2019

Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task force.

Klepin HD; (...); Cordoba R

Review. 10.1016/j.jgo.2020.03.019. 2020

Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal Chemotherapy

Ribera, JM; (...); Spanish Soc Hematology

Article. 10.1016/j.clml.2020.03.011. 2020

Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study.

Martínez-Cuadrón D; (...); Montesinos P

Article. 10.1182/bloodadvances.2021005335. 2022

Trends and Predictive Factors for Outcome of Relapsed Acute Myeloid Leukemia After Allogeneic Hematopoeitic Cell Transplant: Improved Survival for Young Patients in Recent Years

Bazarbachi, A; (...); Mohty, M

Meeting Abstract. 2020

Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?